title: Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.
abstract: During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway.
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
authors.forename: Arpita
authors.initials: A
authors.lastname: Desai
authors.affiliation: Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226-0509, USA.
authors.forename: Smitha P
authors.initials: SP
authors.lastname: Menon
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
authors.forename: Grace K
authors.initials: GK
authors.lastname: Dy
keywords: MEK; RAF; RAS; fibroblast growth factor receptor (FGFR); non-small cell lung cance (NSCLC); receptor tyrosine kinases (RTK)